Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).
infection
mortality
myeloma
registry
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
02
06
2022
received:
31
03
2022
accepted:
09
06
2022
pubmed:
13
7
2022
medline:
24
8
2022
entrez:
12
7
2022
Statut:
ppublish
Résumé
The frequency and causes of early mortality in patients with newly diagnosed multiple myeloma (NDMM) have not been well described in the era of novel agents. We investigated early mortality in a prospective cohort study of all patients with NDMM registered on the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR) at 36 institutions between July 2011 and March 2020. Early mortality was defined as death from any cause within the first 12 months after diagnosis. A total of 2377 patients with NDMM were included in the analysis, with a median (interquartile range) age of 67.4 (58.9-74.60 years, and 60% were male. Overall, 216 (9.1%) patients died within 12 months, with 119 (4.5%) having died within 6 months. Variables that were independent predictors of early mortality after adjustment in multivariable regression included age (odds ratio [OR] 1.07, 95% confidence interval [CI] 1.05-1.08; p < 0.001), Eastern Cooperative Oncology Group performance status (OR 1.50, 95% CI 1.26-1.79; p < 0.001), serum albumin (OR 0.95, 95% CI 0.93-0.98; p < 0.001), cardiac disease (OR 1.96, 95% CI 1.35-2.86; p < 0.001) and International Staging System (OR 1.40, 95% CI 1.07-1.82; p = 0.01). For those with a primary cause of death available, it was reported as disease-related in 151 (78%), infection 13 (7%), other 29 (15%). Infection was listed as a contributing factor for death in 38% of patients.
Identifiants
pubmed: 35818641
doi: 10.1111/bjh.18324
pmc: PMC9541953
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
830-837Informations de copyright
© 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Crit Rev Oncol Hematol. 2018 Oct;130:27-35
pubmed: 30196909
Hematol Oncol. 2018 Feb;36(1):224-231
pubmed: 28429426
PLoS One. 2018 Dec 5;13(12):e0208507
pubmed: 30517181
Lancet Oncol. 2014 Aug;15(9):931-42
pubmed: 25030467
Ann Hematol. 2014 Apr;93(4):627-34
pubmed: 24085241
Am J Hematol. 2017 Mar;92(3):244-250
pubmed: 28006855
J Clin Oncol. 2005 Dec 20;23(36):9219-26
pubmed: 16275935
Haematologica. 2013 Jun;98(6):980-7
pubmed: 23445873
Med J Aust. 2010 Mar 1;192(5):244-5
pubmed: 20201755
Br J Haematol. 2022 Sep;198(5):830-837
pubmed: 35818641
J Clin Oncol. 2010 Feb 10;28(5):830-4
pubmed: 20038719
Eur J Haematol. 2021 Oct;107(4):497-499
pubmed: 34129711
Blood Adv. 2017 Jan 4;1(4):282-287
pubmed: 29296944
J Clin Oncol. 2015 Oct 20;33(30):3459-66
pubmed: 26282661
Am J Hematol. 2015 Apr;90(4):E73-4
pubmed: 25561348
Blood. 2008 Mar 1;111(5):2516-20
pubmed: 17975015
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
BMC Med Res Methodol. 2016 Nov 9;16(1):151
pubmed: 27829380
Am J Hematol. 2017 Sep;92(9):915-923
pubmed: 28543165
Blood. 2015 Mar 26;125(13):2068-74
pubmed: 25628469
BMC Cancer. 2016 Aug 08;16:613
pubmed: 27501959
Eur J Haematol. 2014 Jan;92(1):19-25
pubmed: 24118547
Ann Hematol. 2001 Aug;80(8):452-5
pubmed: 11563589
Leukemia. 2014 May;28(5):1122-8
pubmed: 24157580
J Intern Med. 2010 Dec;268(6):586-93
pubmed: 20831627
Medicine (Baltimore). 2015 Dec;94(50):e2305
pubmed: 26683968
Am J Hematol. 2016 Jul;91(7):700-4
pubmed: 27074204